• Zai Lab published its ESMO 2026 investor presentation, detailing zoci combination results in first-line extensive-stage small cell lung cancer.
• Zoci at 1.6 mg/kg with atezolizumab achieved an 81.8% response rate in 33 patients.
• The same doublet regimen achieved a six-month progression-free survival rate of 81.9%.
• Grade 3 or higher zoci-related adverse events affected 9.1% at that doublet dose, versus 53.8% across carboplatin-containing triplet cohorts.
• A randomized Phase 3 trial is planned to further evaluate the doublet as first-line treatment.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Zai Lab Ltd. published the original content used to generate this news brief on October 23, 2026, and is solely responsible for the information contained therein.